Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etelcalcetide - Amgen

Next Previous
Drug Profile

Etelcalcetide - Amgen

Alternative Names: AMG-416; Etelcalcetide hydrochloride; KAI-4169; KAI-4169-HCl; ONO-5163; Parsabiv; Telcalcetide; Velcalcetide; Velcalcetide hydrochloride

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KAI Pharmaceuticals
  • Developer Amgen; Ono Pharmaceutical
  • Class Disulfides; Peptides
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Secondary hyperparathyroidism

Most Recent Events

  • 27 Jul 2022 Etelcalcetide is still in phase III trial for Secondary hyperparathyroidism (In adolescents, In children) in Belgium, Greece, Germany, Czech Republic, Portugal, Poland, Hungary, France, Lithuania, Spain, Italy and the UK (NCT03969329) (EudraCT2018-004608-21)
  • 27 Jul 2022 No development reported - Phase-III for Secondary hyperparathyroidism in China, Hong Kong, Malaysia (IV) (NCT03299244)
  • 22 Jul 2022 Phase III development is ongoing in Greece and Germany (NCT03969329) (EudraCT2018-004608-21)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top